SARS-CoV-2 Infection of Pluripotent Stem Cell-Derived Human Lung Alveolar Type 2 Cells Elicits a Rapid Epithelial-Intrinsic Inflammatory Response

Jessie Huang,Adam J Hume,Kristine M Abo,Rhiannon B Werder,Carlos Villacorta-Martin,Konstantinos-Dionysios Alysandratos,Mary Lou Beermann,Chantelle Simone-Roach,Jonathan Lindstrom-Vautrin,Judith Olejnik,Ellen L Suder,Esther Bullitt,Anne Hinds,Arjun Sharma,Markus Bosmann,Ruobing Wang,Finn Hawkins,Eric J Burks,Mohsan Saeed,Andrew A Wilson,Elke Mühlberger,Darrell N Kotton,Adam J. Hume,Kristine M. Abo,Rhiannon B. Werder,Ellen L. Suder,Eric J. Burks,Andrew A. Wilson,Darrell N. Kotton
DOI: https://doi.org/10.1016/j.stem.2020.09.013
IF: 23.9
2020-12-01
Cell Stem Cell
Abstract:A hallmark of severe COVID-19 pneumonia is SARS-CoV-2 infection of the facultative progenitors of lung alveoli, the alveolar epithelial type 2 cells (AT2s). However, inability to access these cells from patients, particularly at early stages of disease, limits an understanding of disease inception. Here, we present an <em>in vitro</em> human model that simulates the initial apical infection of alveolar epithelium with SARS-CoV-2 by using induced pluripotent stem cell-derived AT2s that have been adapted to air-liquid interface culture. We find a rapid transcriptomic change in infected cells, characterized by a shift to an inflammatory phenotype with upregulation of NF-κB signaling and loss of the mature alveolar program. Drug testing confirms the efficacy of remdesivir as well as TMPRSS2 protease inhibition, validating a putative mechanism used for viral entry in alveolar cells. Our model system reveals cell-intrinsic responses of a key lung target cell to SARS-CoV-2 infection and should facilitate drug development.
cell biology,cell & tissue engineering
What problem does this paper attempt to address?